Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features

Seipel, Amanda H.; Delahunt, Brett; Samaratunga, Hemamali; Egevad, Lars

doi:10.1016/j.pathol.2016.04.001

Cited by 44 publications

(35 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, DA often appears in the central zone of the prostate. Due to the periurethral location, patients with DA usually present with early symptoms, such as hematuria, urinary obstruction and urinary retention, but with a normal digital examination . Nevertheless, recent research has revealed that peripheral DA is still the most common location of DA …”

Section: Discussionmentioning

confidence: 99%

“…Due to the periurethral location, patients with DA usually present with early symptoms, such as hematuria, urinary obstruction and urinary retention, but with a normal digital examination. 18 Nevertheless, recent research has revealed that peripheral DA is still the most common location of DA. 8 Although the exact clinical implication of DA remains unclear, efforts have been made by many researchers to illustrate its prognostic value in men with nonmetastatic PCa.…”

Section: Discussionmentioning

confidence: 99%

“…Notably, it has been reported that DA is more frequently detected in patients with metastatic PCa (mPCa) than in those with localized PCa . More importantly, DA is more commonly accompanied by visceral metastases and regional metastasis in the penis . However, unlike in the setting of nonmetastatic PCa, there is currently no study focusing on the prognostic value of DA in men with mPCa.…”

Section: Introductionmentioning

confidence: 99%

“…13,14 More importantly, DA is more commonly accompanied by visceral metastases and regional metastasis in the penis. [17][18][19] However, unlike in the setting of nonmetastatic PCa, there is currently no study focusing on the prognostic value of DA in men with mPCa. As a result, whether DA is associated with poor clinical outcomes in patients with mPCa remains largely unknown.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?

Zhao

Liu

et al. 2019

The Prostate

View full text Add to dashboard Cite

Background: The prognostic value of ductal adenocarcinoma of the prostate (DA) in nonmetastatic prostate cancer (PCa) has been identified in many studies. However, it remains unknown whether DA is an adverse prognostic factor in metastatic PCa (mPCa). Method: Data from 634 mPCa patients histopathologically documented with DA or/and acinar adenocarcinoma of the prostate in our center between 2012 and 2018 were retrospectively analyzed. Propensity score matching (PSM) was used to balance the baseline features. Data from the Surveillance, Epidemiology, and End Results (SEER) database were utilized to validate our findings. Castration‐resistant PCa‐free survival (CFS), overall survival (OS), and cancer‐specific survival (CSS) were set as endpoints. Results: DA was confirmed in 35 of 634 (5.5%) patients. Among the DA‐positive patients, 7 of 35 (20%) and 28 of 35 (80%) harbored high (DA ≥ 50%) and low (DA < 50%) DA components, respectively. DA was not associated with poorer median CFS (mCFS) or median OS (mOS) either before PSM (mCFS: 16.9 vs 18.4 month, P = .814; mOS: 42.0 vs 70.1 month, P = .796) or after PSM (mCFS: 16.9 vs 16.9 month, P = .949; mOS: 42.0 vs 79.9 month, P = .960). Likewise, in the SEER data, DA‐positive patients (n = 15 153) shared similar median CSS (25.0 vs 28.0 month, P = .206) and OS (26.0 vs 35.0 month, P = .095) with DA‐negative patients (n = 70). No prognostic difference was found between patients with high and low DA components. Conclusion: We conducted the first study investigating the prognostic value of DA in de novo mPCa. DA was not associated with adverse clinical outcomes in mPCa patients. These findings are helpful for prognostic evaluation, treatment decision making and counseling in mPCa patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?

Zhao

Liu

et al. 2019

The Prostate

View full text Add to dashboard Cite

show abstract

“…Ductal adenocarcinoma of the prostate is an uncommon histological subtype, occurring in approximately 2-6% of prostate cancer, defined on a histological basis by elongated cells and papillary or cribriform architecture [3]. Although it was previously thought to arise from the prostatic utricle, it is now thought to arise from prostatic ducts [4,5].…”

Section: Introductionmentioning

confidence: 99%

Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer

Gillard

Lack

Pontier

et al. 2019

European Urology Focus

View full text Add to dashboard Cite

show abstract

Neoplasms of the Prostate

Aparicio¹,

Pilié²,

Surasi³

et al. 2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Cancer of the prostate is the most commonly diagnosed nonskin neoplasm and the second leading cause of cancer‐related mortality in men in the United States. Considerable advances have been made in screening, diagnosis, and therapy options, particularly in advanced disease, but controversies about the diagnosis and management of prostate cancer, especially in the areas of screening and choice of therapy, continue to evolve. Research initiatives in advanced disease have shifted from prognostication to prediction, and current treatment considerations are focused on optimization of therapy sequence, development of rational combinations, biomarker‐driven patient selection, determining the role of local disease control in patients with metastases, and bone targeting therapies. Despite progress, prostate cancer survival has not improved at the same pace as other cancer subtypes. It is anticipated that addressing knowledge gaps will lead to the development of novel agents with unique mechanisms of action and optimization of integrated strategies (surgical, radiation, and medical) to improve overall survival. Prostate cancer awareness, clinical application of improved biopsy schemes, and advances in imaging combined with the widespread use of prostate‐specific antigen (PSA) have resulted in increased detection of early prostate cancer. The question of whether PSA screening would reduce mortality from prostate cancer has now been tested in the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial first published in 2009. Though many of the apparent discrepancies between these trials can be accounted for by trial design and patient cross‐contamination, they brought to the forefront the dilemma of overdiagnosis and overtreatment, as well as the heterogeneous nature of prostate cancer and the urgent need to improve the accuracy of identifying clinically significant early disease with lethal potential. It is hoped that enhancing the current morphologic and anatomic classification of prostate cancer with a better understanding of the molecular underpinnings of diverse disease states will lead to a more refined taxonomy of prostate cancer and ultimately improve outcomes while minimizing treatment‐related morbidity. Salient features that distinguish prostate cancer from other malignancies and frame the dilemmas surrounding it are its striking age‐dependent incidence, with progressively increasing frequency with increasing age, a strong familial and hereditary component, the variable lethality of morphologically identical cancers, the central role of androgen signaling, the preponderance of bone‐forming metastases, and metabolic derangements contributing to lethal progression. Important advances made in each of these areas will modify the approaches currently used to prevent, prognosticate, predict, and treat prostate cancer.

show abstract

Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features

Cited by 44 publications

References 74 publications

Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?

Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?

Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer

Neoplasms of the Prostate

Contact Info

Product

Resources

About